» Articles » PMID: 32050092

Tumor Microenvironment: Challenges and Opportunities in Targeting Metastasis of Triple Negative Breast Cancer

Overview
Journal Pharmacol Res
Publisher Elsevier
Specialty Pharmacology
Date 2020 Feb 13
PMID 32050092
Citations 224
Authors
Affiliations
Soon will be listed here.
Abstract

Triple negative breast cancer (TNBC) is most aggressive subtype of breast cancers with high probability of metastasis as well as lack of specific targets and targeted therapeutics. TNBC is characterized with unique tumor microenvironment (TME), which differs from other subtypes. TME is associated with induction of proliferation, angiogenesis, inhibition of apoptosis and immune system suppression, and drug resistance. Exosomes are promising nanovesicles, which orchestrate the TME by communicating with different cells within TME. The components of TME including transformed ECM, soluble factors, immune suppressive cells, epigenetic modifications and re-programmed fibroblasts together hamper antitumor response and helps progression and metastasis of TNBCs. Therefore, TME could be a therapeutic target of TNBC. The current review presents latest updates on the role of exosomes in modulation of TME, approaches for targeting TME and combination of immune checkpoint inhibitors and target chemotherapeutics. Finally, we also discussed various phytochemicals that alter genetic, transcriptomic and proteomic profiles of TME along with current challenges and future implications. Thus, as TME is associated with the hallmarks of TNBC, the understanding of the impact of different components can improve the clinical benefits of TNBC patients.

Citing Articles

PFDN1 silencing disrupts critical cancer pathways in triple-negative breast cancer: investigating migration, cell cycle, and apoptosis as a new target therapy.

Alokda A, Soffar A, Yousef A, Ibrahim F, El-Sewedy T, Elmetwalli A Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 40063241 DOI: 10.1007/s00210-025-03975-6.


Role of Triple-Negative Breast Cancer-Derived Extracellular Vesicles in Metastasis: Implications for Therapeutics and Biomarker Development.

Wan X, Yang L, Wu L, Lei J, Li J J Cell Mol Med. 2025; 29(5):e70448.

PMID: 40032646 PMC: 11875785. DOI: 10.1111/jcmm.70448.


Axillary lymph node metastasis in breast cancer: from historical axillary surgery to updated advances in the preoperative diagnosis and axillary management.

Wu T, Long Q, Zeng L, Zhu J, Gao H, Deng Y BMC Surg. 2025; 25(1):81.

PMID: 40016717 PMC: 11869450. DOI: 10.1186/s12893-025-02802-2.


Discovery of a new mitophagy-related gene signature for predicting the outlook and immunotherapy in triple-negative breast cancer.

Liu G, Yu G, Yin D, Ma J Sci Rep. 2025; 15(1):6794.

PMID: 40000809 PMC: 11861672. DOI: 10.1038/s41598-025-91613-9.


Integrated multiomics analysis highlights the immunosuppressive role of granulin precursor positive macrophages in hepatocellular carcinoma.

Li J, Huang W, Kuang J, Zhou S, Li Y, Xia Y PeerJ. 2025; 13:e18879.

PMID: 39995994 PMC: 11849516. DOI: 10.7717/peerj.18879.